Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus.

Literature DB >> 22190401

Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus.

Rita Czakó¹, Robert L Atmar, Antone R Opekun, Mark A Gilger, David Y Graham, Mary K Estes.

Abstract

A hemagglutination inhibition (HAI) assay to assess serum antibody responses following Norwalk virus (NV) infection was developed. HAI activity increased significantly in individuals experimentally infected with NV (n = 18) and correlated with antibody levels measured in a histo-blood group antigen (HBGA) blocking assay. Prechallenge HAI antibody levels also correlated with protection from the development of gastroenteritis (Mann-Whitney test, P = 0.02). The HAI assay is another assay suitable for the detection of antibody that correlates with protection from Norwalk virus-associated disease.

Entities: Disease Species

Mesh：

Substances：
Antibodies, Viral

Year: 2011 PMID： 22190401 PMCID： PMC3272916 DOI： 10.1128/CVI.05592-11

Source DB: PubMed Journal: Clin Vaccine Immunol ISSN： 1556-679X

17 in total

1. Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens.

Authors: Anne M Hutson; Robert L Atmar; Donald M Marcus; Mary K Estes
Journal: J Virol Date: 2003-01 Impact factor: 5.103

2. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein.

Authors: X Jiang; M Wang; D Y Graham; M K Estes
Journal: J Virol Date: 1992-11 Impact factor: 5.103

3. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns.

Authors: Pengwei Huang; Tibor Farkas; Weiming Zhong; Ming Tan; Scott Thornton; Ardythe L Morrow; Xi Jiang
Journal: J Virol Date: 2005-06 Impact factor: 5.103

4. A homozygous nonsense mutation (428G-->A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections.

Authors: Maria Thorven; Ammi Grahn; Kjell-Olof Hedlund; Hugo Johansson; Christer Wahlfrid; Göran Larson; Lennart Svensson
Journal: J Virol Date: 2005-12 Impact factor: 5.103

Review 5. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer.

Authors: S Hakomori
Journal: Biochim Biophys Acta Date: 1999-12-06

6. Norovirus vaccine against experimental human Norwalk Virus illness.

Authors: Robert L Atmar; David I Bernstein; Clayton D Harro; Mohamed S Al-Ibrahim; Wilbur H Chen; Jennifer Ferreira; Mary K Estes; David Y Graham; Antone R Opekun; Charles Richardson; Paul M Mendelman
Journal: N Engl J Med Date: 2011-12-08 Impact factor: 91.245

7. Norwalk virus infection associates with secretor status genotyped from sera.

Authors: Anne M Hutson; Fabrice Airaud; Jacques LePendu; Mary K Estes; Robert L Atmar
Journal: J Med Virol Date: 2005-09 Impact factor: 2.327

8. Human susceptibility and resistance to Norwalk virus infection.

Authors: Lisa Lindesmith; Christine Moe; Severine Marionneau; Nathalie Ruvoen; Xi Jiang; Lauren Lindblad; Paul Stewart; Jacques LePendu; Ralph Baric
Journal: Nat Med Date: 2003-04-14 Impact factor: 53.440

9. Outbreak studies of a GII-3 and a GII-4 norovirus revealed an association between HBGA phenotypes and viral infection.

Authors: Ming Tan; Miao Jin; Huaping Xie; Zhaojun Duan; Xi Jiang; Zhaoyin Fang
Journal: J Med Virol Date: 2008-07 Impact factor: 2.327

10. Norwalk virus shedding after experimental human infection.

Authors: Robert L Atmar; Antone R Opekun; Mark A Gilger; Mary K Estes; Sue E Crawford; Frederick H Neill; David Y Graham
Journal: Emerg Infect Dis Date: 2008-10 Impact factor: 6.883

32 in total

1. Nanobody-Mediated Neutralization Reveals an Achilles Heel for Norovirus.

Authors: Anna D Koromyslova; Jessica M Devant; Turgay Kilic; Charles D Sabin; Virginie Malak; Grant S Hansman
Journal: J Virol Date: 2020-06-16 Impact factor: 5.103

2. Serological Correlates of Protection against a GII.4 Norovirus.

Authors: Robert L Atmar; David I Bernstein; G Marshall Lyon; John J Treanor; Mohamed S Al-Ibrahim; David Y Graham; Jan Vinjé; Xi Jiang; Nicole Gregoricus; Robert W Frenck; Christine L Moe; Wilbur H Chen; Jennifer Ferreira; Jill Barrett; Antone R Opekun; Mary K Estes; Astrid Borkowski; Frank Baehner; Robert Goodwin; Anthony Edmonds; Paul M Mendelman
Journal: Clin Vaccine Immunol Date: 2015-06-03

Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus.

1. Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens.

2. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein.

3. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns.

4. A homozygous nonsense mutation (428G-->A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections.

Review 5. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer.

6. Norovirus vaccine against experimental human Norwalk Virus illness.

7. Norwalk virus infection associates with secretor status genotyped from sera.

8. Human susceptibility and resistance to Norwalk virus infection.

9. Outbreak studies of a GII-3 and a GII-4 norovirus revealed an association between HBGA phenotypes and viral infection.

10. Norwalk virus shedding after experimental human infection.

1. Nanobody-Mediated Neutralization Reveals an Achilles Heel for Norovirus.

2. Serological Correlates of Protection against a GII.4 Norovirus.

Review 3. Prospects and Challenges in the Development of a Norovirus Vaccine.

4. Seroepidemiology of norovirus-associated travelers' diarrhea.

5. Determination of the 50% human infectious dose for Norwalk virus.

6. Human Norovirus Neutralized by a Monoclonal Antibody Targeting the Histo-Blood Group Antigen Pocket.

7. Replication of Human Norovirus RNA in Mammalian Cells Reveals Lack of Interferon Response.

8. Norovirus vaccine development: next steps.

Review 9. Norovirus immunology: Of mice and mechanisms.

Review 10. Epidemiology of human noroviruses and updates on vaccine development.